SHP2 Inhibitors Undergo Exploration in Combinations
Melissa Johnson, MD, discussed SHP2 inhibitors with Targeted Therapies in Oncology.
Biomarkers in Renal Cell Carcinoma: Present Utility and Future Possibility
Wenxin (Vincent) Xu, MD, provides insight on biomarkers in renal cell carcinoma.
A Decade of Breast Cancer at the Molecular Level: Pioneering Personalized Medicine
As we identify more targets...there will probably be more and newer, perhaps even better, therapeutics than we have currently, said Dennis J. Slamon, MD.